Users Online Now:
1,590
(
Who's On?
)
Visitors Today:
337,707
Pageviews Today:
733,947
Threads Today:
267
Posts Today:
4,692
01:38 PM
Directory
Adv. Search
Topics
Forum
Back to Forum
Back to Thread
REPLY TO THREAD
Subject
Here We GO: Moderna CEO Announces New mRNA Shot for Heart Failure Patients to Help “Grow Back New Blood Vessels”
User Name
Font color:
Default
Dark Red
Red
Orange
Brown
Yellow
Green
Olive
Cyan
Blue
Dark Blue
Indigo
Violet
Black
Font:
Default
Verdana
Tahoma
Ms Sans Serif
In accordance with industry accepted best practices we ask that users limit their copy / paste of copyrighted material to the relevant portions of the article you wish to discuss and no more than 50% of the source material, provide a link back to the original article and provide your original comments / criticism in your post with the article.
[quote:LOLZ LOLZ LOLZLOLZ LOLZ LOLZ 85095171:MV81MzMzNDUyXzY2NkI5NUMw] Stéphane Bancel, CEO of Moderna, announced the development of a new mRNA shot to treat patients suffering from heart failure. In a statement released on Monday, the pharmaceutical company said it currently has 48 programs in development, including 36 programs that are currently being tested in clinical trials. These programs include mRNA infectious disease vaccines and mRNA therapeutics that span seven different modalities. “We enter 2023 in a great position, with significant momentum across our clinical pipeline, a highly energized team and a strong balance sheet of over $18 billion of cash and cash equivalents,” said Stéphane Bancel, Chief Executive Officer of Moderna. https://www.thegatewaypundit.com/2023/01/go-moderna-ceo-announces-new-mrna-shot-heart-failure-patients-help-grow-back-new-blood-vessels/ [/quote]
Original Message
Stéphane Bancel, CEO of Moderna, announced the development of a new mRNA shot to treat patients suffering from heart failure.
In a statement released on Monday, the pharmaceutical company said it currently has 48 programs in development, including 36 programs that are currently being tested in clinical trials.
These programs include mRNA infectious disease vaccines and mRNA therapeutics that span seven different modalities.
“We enter 2023 in a great position, with significant momentum across our clinical pipeline, a highly energized team and a strong balance sheet of over $18 billion of cash and cash equivalents,” said Stéphane Bancel, Chief Executive Officer of Moderna.
[
link to www.thegatewaypundit.com (secure)
]
Pictures (click to insert)
General
Politics
Bananas
People
Potentially Offensive
Emotions
Big Round Smilies
Aliens and Space
Friendship & Love
Textual
Doom
Misc Small Smilies
Religion
Love
Random
View All Categories
|
Next Page >>